This article explains how genetic surgery, exemplified by Baby KJ's case, differs from traditional gene therapy by offering personalized interventions for rare genetic diseases. It discusses the need for a new regulatory framework that allows for customized treatments without the lengthy approval processes currently required by the FDA. The author proposes a certification model for genetic surgery centers to streamline patient care and enhance treatment options.